Search Results

Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s neurophysiological platform to develop a better understanding of the relationship between sleep and neurological conditions with an initial focus in rare epileptic syndromes.

Under the deal, the Danish pharma will gain access to Longboard’s 5-HT2C receptor superagonist that is currently in late-stage development for seizures in various developmental and epileptic encephalopathies, including Dravet syndrome.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to four new employees.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported first quarter 2024 financial results.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to seven new employees.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that members of its senior leadership team will present at two upcoming investor conferences in February.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH) today announced that Dr. Randall Kaye, Longboard’s Chief Medical Officer, will present late-breaking data from the PACIFIC Study evaluating bexicaserin, an oral, centrally acting 5-HT2C receptor superagonist, in participants with Developmental and Epileptic Encephalopathies (DEEs) at the AAN Annual Meeting taking place April 13-18, 2024, virtually and in Denver, Colorado.

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, announced the grant of inducement awards to three new employees.

Longboard Pharmaceuticals, Inc. announced the pricing of an upsized underwritten public offering of 10,000,000 shares of its voting common stock at a price to the public of $21.00 per share.